NCT03739827
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: SMARCA4, SMARCB1
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: Must be a patient at Cedars-Sinai Medical Center
Exclusions: 
https://ClinicalTrials.gov/show/NCT03739827